
News|Articles|February 13, 2019
Revcovi for Adenosine Deaminase Severe Combined Immune Deficiency
Author(s)Drew Boxler
Advertisement
Revcovi (elapegademase-lvlr, Lediant Biosciences)
Indications: Adenosine deaminase severe combined immune deficiency (ADA-SCID)
Dosage:
- Starting: 0.4 mg/kg (idea body weight) in 2 intramuscular supplements (0.2 mg/kg twice per week)
- Maintenance dosing: increments of 0.033 mg/kg weekly if...
- trough ADA activity is under 30 mmol/hr/L
- trough deoxyadenosine nucleotides (dAXP) are above 0.02 mmol/L
- the immune reconstitution is inadequate based on the clinical assessment of the patient
Contraindications: N/A
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
REM-Dominant Sleep Apnea Significantly More Prominent Following COVID-19
2
Most Favored Nation: Global Benchmarking to Reimagine US Drug Distribution
3
Pharmacists Empower Patients to Improve Insulin Management
4
Expert Addresses Pharmacy’s Uncertainty Amid MFN Drug Pricing Policy
5






















































































































